Ernexa Therapeutics Inc. (ERNA) Receivables - Doubtful (2012 - 2018)

Ernexa Therapeutics' (ERNA) quarterly Receivables - Doubtful came in at $361000.0 in Q3 2018, down 22.03% on a QoQ basis from $463000.0 in Q4 2017.

Ernexa Therapeutics Inc. (ERNA) Receivables - Doubtful (2012 - 2018) Analysis & Trends

Ernexa Therapeutics (ERNA) has 6 years of Receivables - Doubtful data on file, last reported at $361000.0 in Q3 2018.

Quarterly Receivables - Doubtful changed N/A year-over-year to $361000.0 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $361000.0 (changed N/A YoY) and the FY2017 annual result came in at $463000.0, up 23.14% from the prior year.
Receivables - Doubtful retreated to $361000.0 in Q3 2018, from $463000.0 in the prior quarter.
In the past five years, Receivables - Doubtful ranged from a high of $463000.0 in Q4 2017 to a low of $300000.0 in Q2 2014.
A 4-year average of $375000.0 and a median of $368500.0 in 2016 frame the typical range for Receivables - Doubtful.
The widest YoY moves for Receivables - Doubtful: up 23.14% in 2017, down 23.14% in 2017.
Tracing ERNA's Receivables - Doubtful over 4 years: stood at $300000.0 in 2014, then grew by 25.33% to $376000.0 in 2016, then increased by 23.14% to $463000.0 in 2017, then decreased by 22.03% to $361000.0 in 2018.
The last three Receivables - Doubtful figures came in at $361000.0 (Q3 2018), $463000.0 (Q4 2017), and $376000.0 (Q4 2016), per Business Quant data.

Download Data